International Journal of Advanced Research in Education and TechnologY (IJARETY)

An Examination of the Challenges of Leadership in a Rapidly Changing Business Environment and Marketing Strategies: Examples from the Pharma Industry

Ms. Shamal Bapusaheb Yeole[1], Prof. Rajendra Jarad[2], Prof. Dhananjay Bhavsar[3],

Prof. Praveen Suryavanshi[4], Prof . Mahendra Yadav[5], Prof. Nilambari Moholkar[6]

(Department of MBA), Dr. D. Y. Patil Institute of Technology, Pimpri, Pune, India[1,2,3,4,5,6]

ABSTRACT: Recently the pharmaceutical industries have developed different leadership programs and marketing strategies to grow the industry at a national and international level. In this paper we emphasize the different approaches towards the leadership programs and marketing strategies of pharmaceutical industries up to 2024 and dominating factors affecting it.

KEYWORDS: Pharmaceutical industry, Data analytics, Artificial intelligence, Marketing

Graphical abstract:

Sr.No	Content
I	**Introduction**
II	**Indian Pharmaceutical Industry**

I. INTRODUCTION

The Indian pharmaceutical industry is the world's 3rd largest by volume and 14th largest in terms of value. Total Annual Turnover of Pharmaceuticals was Rs. 2,89,998 crores for the year 2019-2020. Total pharmaceutical exports and imports were to the tune of Rs. 1,46,260 crore and Rs. 42,943 crores respectively in the year 2019-20.

India has the second-highest number of US FDA approved plants outside the US. India is a global leader in the supply of DPT, BCG, and Measles vaccines. India accounts for 60 percent of global vaccine production, contributing 40 to 70 percent of the WHO demand for Diphtheria, Tetanus and Pertussis (DPT) and Bacillus Calmette–Guérin (BCG) vaccines, and 90 percent of the WHO demand for the measles vaccine.

India is the largest provider of generic drugs globally. Access to affordable HIV treatment from India is one of the greatest success stories in medicine. India is one of the biggest suppliers of low-cost vaccines in the world. Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country the "Pharmacy of the World". The pharmaceutical sector currently contributes to around 1.72% of the country's GDP.

II. INDIAN PHARMACEUTICAL INDUSTRY

India's pharmaceutical sector forms a major component of the country's foreign trade, with attractive avenues and opportunities for investors. India supplies affordable and low-cost generic drugs to millions of people across the globe and operates a significant number of United States Food and Drug Administration (USFDA) and World Health Organization (WHO) Good Manufacturing Practices (GMP)-compliant plants. India has occupied a premier position among pharmaceutical manufacturing countries of the world.

India is 3rd largest market for APIs globally, 8% share in Global API Industry, 500+ different APIs are manufactured in India and it contributes 57% of APIs to prequalified list of the
WHO

It is expected to reach USD 65 Bn by 2024 and to USD 130 Bn by 2030.India is the largest manufacturer of generic medicines globally. Its pharmaceutical industry plays a crucial role in global healthcare, providing affordable generic medicines that impact the lives of the global.

III. ROLE OF LEADERSHIP IN PHARMA INDUSTRIES

Top Leadership Competencies
- Building a collaborative relationship
- Strategic perspective
- Taking initiative
- Participative management
- Leading employees
- Change management
- Decisiveness
- Being a quick study

Building collaborative relationships was rated as the most important quality needed for effective leadership. It topped the list for 90% of the pharma executives who provided Benchmarks performance data on leaders in their organizations.

Pharma organizations that survive and thrive will develop these important leadership competencies and will prepare their leadership team to handle the performance challenges inherent in the 21st century trends the industry faces from healthcare reform, a struggling economy, and global competition to technological advances, partnerships and alliances, and diversity in the workplace.

Our study shows the greatest potential derailment factor for pharma executives is "having to narrow a functional orientation

IV. MARKETING STRATEGIES IN PHARMA INDUSTRIES

For understandable reasons of regulation, the pharmaceutical industry has been slow to adopt digital marketing strategies. Nonetheless, pharmaceutical companies will experience a boost in sales and overall growth when they adopt pharmaceutical digital marketing.

Targeted and Personalized Marketing
In 2023, pharma marketers enjoy higher conversion by sending personalized messages through various digital channels (omnichannel marketing).

Through digital marketing, **you can tailor your email campaigns to audience segments** (grouped by profession, specialty, age, gender, and the like). For example, an immunologist may need a rapid response to queries, while marketing and a general practitioner may require you to identify when they'll be free to engage.

Data-driven Marketing
Digital marketing enables pharma companies to understand HCP and patients' preferences, especially with CRM and CLM tools. With data-driven marketing, you can understand how HCPs perceive different diseases, how fatal they are, and the best treatment choice.

Companies can then maximize such data-rich knowledge to develop effective marketing strategies and health education programs. The sales rep armed with data stands a better chance of convincing HCPs as they'll supply relevant and previously unknown information.

Return-on-investment (ROI)
Tracking what works out of your digital marketing campaigns is now easier than ever. You can know which channels deliver the best results for your market segment. Furthermore, you can even track content performance in real-time, such as the opening rates of marketing emails. This way, the marketing team is sure of where and where not to spend money.

V. EFFECT OF DIGITAL MARKETING IN GROWTH OF INDUSTRIES

Pharmaceutical digital marketing uses the potential of technology to educate audiences and promote products and services. In pharma, these audiences are primarily healthcare professionals (HCPs) and patients, though investors and other stakeholders are also influential.

Digital marketing in pharma uses many digital techniques and channels familiar to other sectors, though often in ways specific to the life sciences. As a regulated industry, pharma must ensure full compliance in its digital communications and patient outreach. For example, it is common to create different web pages for particular audiences. Patients and their carers will get a page designed for their needs, while medical professionals will receive information relevant and appropriate for prescribers that only they can access

Popular pharma digital marketing channels

The digital channels and techniques are specific to pharma — often developed to support the high- quality scientific and medical dialogues that companies provide HCPs. For example, eDetailing (electronic detailing on

a mobile device) enables pharma reps and medical science liaisons (MSLs) to deliver one-to-one presentations in HCP offices, pharmacies, hospitals and other points of care

According to reports by Invest India.Gov.In, India's pharmaceutical industry is expected to reach $65 billion by the end of 2024 and $130 billion by 2030. This meteoric rise not only underscores the industry's immense growth potential but also its pivotal role on the global stage.

As India emerges as a powerhouse in pharmaceutical innovation and production, the integration of digital marketing strategies becomes not just a choice, but an imperative for companies looking to thrive in this dynamic landscape. Let's take a closer look at how digital marketing can help transform and boost India's pharmaceutical sector.

VI. ARTIFICIAL INTELLIGENCE IN MARKETING OF GROWING INDUSTRIES

Inaccurate models.
Pharmaceutical companies are exposed to the risk of gen AI hallucinations resulting from poor or incomplete data. They can mitigate that kind of risk by placing guardrails around gen AI content— for example, ensuring that humans review it before it is distributed to providers or patients. The bottom line: gen AI should never be the final decision maker; it should instead accelerate decision making by human workers.

IP infringement and data privacy.
Foundational models typically include large volumes of internet-based data, and that has led to alleged copyright violations, plagiarism, and other forms of IP infringement. This risk is particularly high among life science companies because of the exceptionally stringent data privacy regulations surrounding patients' medical data; many countries, for example, require this information to remain on domestic servers. To avoid infringing IP, businesses using foundational models need proper guardrails, such as training models on their own intellectual property and writing IP protections into contracts with external vendors.

Regulatory compliance.
AI regulations with specific ramifications for generative AI are being planned for near-term enactment, although they vary by country—for instance, the European Union's proposed AI Act, US federal and state law, and China's draft administrative measures for generative AI services.

Commercial pharma faces additional risks as a result of increased regulation by the US Food and Drug Administration and similar agencies on the contents of advertising and promotional materials. Pharma companies can mitigate these risks by embedding guardrails directly in content- generating models and ensuring that humans always make the final decisions

It's helpful to look at gen AI through the lens of another disruptive technology, which swept through society at the turn of the last century: electricity. The first light bulbs were invented in the 1870s, and several years later the first electric motors started to power manufacturing machinery. Yet as business historians and innovation experts like to point out, by 1900 electricity powered less than 5 percent of manufacturing, and even as late as the 1910s most facilities continued to rely on steam. Why weren't business leaders more eager to use the new technology? After all, electric motors were far cleaner, safer, and more efficient than steam engines.

Nonetheless, gen AI could give the pharma industry a once-in-a-century chance to address those long-standing obstacles and create new breakthroughs in science and patient care. Much as it would have been foolish for factory owners to stick with steam in the 1910s, pharma companies would be unwise not to recognize the transformative potential of AI. They should begin working now to understand, implement, and scale it.

VII. RECENT STATISTIC IN PHARMACEUTICALS

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.

India's domestic pharmaceutical market stood at US$ 42 billion in 2021 and is likely to reach US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030

India's pharmaceutical industry has gained international recognition as the "*Pharmacy of the World*," particularly for its imperative role in supplying vaccines, essential medicines, and medical supplies during the COVID-19 pandemic and beyond. The sector has showcased its innovative capabilities and established itself as a crucial global pharmaceutical value chain member.

Ranking third globally in drug and pharmaceutical production by volume, India exports to approximately 200 countries and territories. The top five destinations for these exports are the USA, Belgium, South Africa, the UK, and Brazil.

India's biotechnology sector has increased 13-fold over the past decade, from $10 billion in 2014 to over $130 billion in 2024. It is projected to reach $300 billion by 2030 [2]. Growth in the Indian pharmaceutical industry is being driven by metropolitan cities, Tier I cities, and rural markets, each accounting for approximately 30% of the market share.

With a 10-12% growth rate, India's pharmaceutical sector is expected to reach $100 billion by 2025, fuelled by its robust domestic manufacturing base

Riding on the back of various schemes and reforms, India's Drug and pharmaceutical exports increased by 8.36% from $2.13 billion in July 2023 to $2.31 billion in July 2024

Pharma 4.0 Market Size, Share | Growth CAGR Of 18.G

VIII. CONCLUSION

Based on New market strategies and leadership programs, we conclude that the overall growth of pharmaceutical industry shows a dynamic change in recent years as well as in future prospective also. The role of Digital marketing, leadership programs, Artificial Intelligence etc. are extraordinary tools for all the industries for the development.

REFERENCES

1. *Annual report 2020-21*, Government of India, Ministry of Chemicals C
   Fertilizers Department of Pharmaceuticals
2. *Annual report 2022-23*, Government of India, Ministry of Chemicals C Fertilizers
3. Department of Pharmaceuticals
4. Bala M., Verma D. *"A Critical review of Digital Marketing,"* www.ijmrs.us
5. yan, D. (2014). Understanding Digital Marketing: Marketing
   Strategies for Engaging the Digital Generation Ed. 3. 1st ed
6. 2021 IJCRT | Volume 9, Issue 5 May 2021 | ISSN: 2320-2882
7. Pramana Research Journal Volume 9, Issue 1, 2019 ISSN NO: 2249 -2976
8. International Journal of Trend in Scientific Research and Development (IJTSRD) Conference Issue | March 2019
   Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470.

IJARETY

International Journal of Advanced Research in Education and Technology

www.ijarety.in   editor.ijarety@gmail.com